The market expects Beam Therapeutics Inc. (BEAM) to deliver a year-over-year increase in earnings on higher revenues when it ...

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best oversold NASDAQ stocks to buy now. On July 1, Beam Therapeutics Inc. (NASDAQ:BEAM) announced an Agreement and Plan of Merger under which it ...

Beam Therapeutics is positioned at the top for Revenue Growth among its peers, with a growth rate of 107.68%. However, it ranks at the bottom for Gross Profit margin, standing at -10.63%.

Beam Therapeutics (BEAM) Company Description: Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease.

Summary Beam Therapeutics focuses on base editing technology, which allows for precise changes at the DNA level and potentially reduces off-target effects. Base editing has the versatility to ...

Beam Therapeutics (BEAM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Beam Therapeutics has a mixed history of earnings surprises. The company beat on earnings in three of the trailing four quarters while missing the same on the remaining occasion, delivering an ...

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing ...

Beam Therapeutics stock is trading near 52-week lows. Should I get out of my current bear-market mindset and get in on a few BEAM shares? Find out my thoughts.

10 stocks we like better than Beam Therapeutics When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor ...

Let's take a look. The case for Beam Therapeutics Beam Therapeutics focuses on precision gene-editing therapies to treat serious diseases. Its stock is down about 36% during the past year.

Beam Therapeutics (BEAM 0.70%) recently signed a major research deal with Pfizer (PFE 0.30%) that could be worth up to $1.35 billion, and hardly anyone seemed to notice.